Literature DB >> 15802331

Vascular endothelial growth factor in pleural effusions of different origin.

U Sack1, M Hoffmann, X J Zhao, K S Chan, D S C Hui, H Gosse, L Engelmann, J Schauer, F Emmrich, G Hoheisel.   

Abstract

This study aimed to determine the diagnostic relevance of vascular endothelial growth factor (VEGF) in the pleural fluid and serum of patients with pleural effusions of different aetiology. VEGF was quantified in the pleural effusion fluid and serum of 96 patients with malignancies (58 lung cancers (CA) and 38 tumours with secondaries to the lung (TM)), 45 with congestive heart failure (CHF), 28 with tuberculosis (TB), 45 with acute infections (INF), and in the serum of 20 healthy controls. VEGF pleural effusion concentrations were significantly different in the main diagnostic groups. VEGF was higher in effusions of patients with malignancies (CA as well as TM) in comparison with INF, TB or CHF. In serum, however, high VEGF concentrations indicated CA, TM or INF, but not TB or CHF. Despite significant differences of VEGF levels in different patient groups, receiver-operating characteristic analysis revealed insufficient diagnostic value of VEGF for differential diagnosis of pleural effusions. In conclusion, vascular endothelial growth factor serum concentration is highly suggestive of the presence of lung disease in general, except for tuberculosis. In effusion fluid, the presence of vascular endothelial growth factor clearly indicates inflammatory or malignant origin. However, for diagnostic use, additional parameters besides vascular endothelial growth factor are mandatory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802331     DOI: 10.1183/09031936.05.00037004

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  29 in total

1.  A potential role for VEGF in the diagnostic approach of pleural effusions.

Authors:  Aggeliki Psatha; Demosthenes Makris; Theodora Kerenidi; Zoe Daniil; Theodoros Kiropoulos; Konstantinos Gourgoulianis
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer.

Authors:  Daniel T Rein; Anne Kathrin Volkmer; Jens Volkmer; Ines M Beyer; Wolfgang Janni; Markus C Fleisch; Anne Kathrin Welter; Dirk Bauerschlag; Thomas Schöndorf; Martina Breidenbach
Journal:  Oncol Lett       Date:  2012-01-03       Impact factor: 2.967

3.  A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.

Authors:  S F Mulder; M J Boers-Sonderen; H F M van der Heijden; K C P Vissers; C J A Punt; C M L van Herpen
Journal:  Target Oncol       Date:  2014-01-21       Impact factor: 4.493

4.  Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysis.

Authors:  Yong-Chun Shen; Meng-Qi Liu; Chun Wan; Lei Chen; Tao Wang; Fu-Qiang Wen
Journal:  Exp Ther Med       Date:  2012-03-14       Impact factor: 2.447

5.  Differential expression of vascular endothelial growth factor-A, -C and -D for the diagnosis and prognosis of cancer patients with malignant effusions.

Authors:  Lin Jia; Yun DU; Tao Li; Yalei Lv; Yudong Wang; Yan Zhang; Xinliang Zhou; Wei Liu
Journal:  Oncol Lett       Date:  2015-06-02       Impact factor: 2.967

Review 6.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

7.  Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.

Authors:  Motohiro Tamiya; Akihiro Tamiya; Tadahiro Yamadori; Keiko Nakao; Kazuhiro Asami; Tomomi Yasue; Tomoyuki Otsuka; Takayuki Shiroyama; Naoko Morishita; Hidekazu Suzuki; Norio Okamoto; Kyoichi Okishio; Tomoya Kawaguchi; Shinji Atagi; Ichiro Kawase; Tomonori Hirashima
Journal:  Med Oncol       Date:  2013-08-08       Impact factor: 3.064

8.  Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion.

Authors:  Fang Fang; Ping Chen; Xin Wu; Li Yang; Xun Yang; Zhen-Xiang Xi; Bin-Wen Zhou; Xi-Kun Zhou; Zhi-Yong Qian; Bo Xiao; Yu-Quan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-15       Impact factor: 4.553

9.  Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions.

Authors:  Stacey D Finley; Aleksander S Popel
Journal:  J Natl Cancer Inst       Date:  2013-05-13       Impact factor: 13.506

10.  Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions.

Authors:  Lisete Ribeiro Teixeira; Murilo B Dias; Roberta K B Sales; Leila Antonangelo; Vanessa A Alvarenga; Juliana Puka; Evaldo Marchi; Milena Marques Pagliarelli Acencio
Journal:  Lung       Date:  2016-09-27       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.